Now showing items 1-6 of 6
Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first South African national survey
(Public Library of Science, 2016)
Background: In order to assess the level of transmitted and/or pre-treatment antiretroviral drug resistance to HIV-1, the World Health Organization (WHO) recommends that regular surveys are conducted. This study’s objective ...
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation
(Public Library of Science, 2017-07-28)
Introduction: HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment guidelines evolve. Methods: An expert panel was ...
Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa
(Frontiers Media, 2020)
The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the ...
Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia
(Public Library of Science, 2020-09-11)
ENGLISH ABSTRACT: In patients who are HIV infected, hepatitis B virus (HBV) infection is an important co-morbidity. However, antiretroviral options for HIV/HBV co-infected children are limited and, at the time of this ...
Rapid emergence of resistance to antiretroviral treatment after undisclosed prior exposure : a case report
(AOSIS Publishing, 2019)
Introduction: Patients who disengaged from care may present as therapy naïve for antiretroviral treatment (ART) initiation at a different site, without being recognised as being at an increased risk of rapid treatment ...
Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa
(BMC (part of Springer Nature), 2019)
Background: HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) ...